Brian B. Rogers

Associate

Century City
brian.rogers@lw.com
+1.213.891.8117

PRACTICES

  • International Tax
  • Tax
  • Tax-Exempt Organizations
  • Transactional Tax

INDUSTRIES

  • REITs

BAR QUALIFICATIONS

  • California

EDUCATION

  • JD, Stanford Law School, 2015
  • PhD, University of California, Irvine, 2011
  • BA, University of Northern Iowa, 2004
    summa cum laude

LANGUAGES SPOKEN

  • English

PROFILE

Brian Rogers is an associate in the Los Angeles office of Latham & Watkins and a member of the firm's Tax Department.

Brian’s practice focuses on domestic and international transactional tax matters. He has advised business organizations on:

  • Mergers and acquisitions
  • REITs
  • Private equity investments
  • Financings
  • Securities offerings

His pro bono activities include advising charitable organizations and preparing income tax returns for individuals.

He previously served as a legal extern with the IRS Office of Chief Counsel, assisting with transfer pricing audits of large multinationals.

Brian received his JD from Stanford University Law School, where he served as executive submissions editor for the Stanford Journal of Law, Business & Finance.

Prior to joining the firm, Brian obtained a PhD in logic and philosophy of science from the University of California, Irvine and was an instructor at California State University, Long Beach.

Thought Leadership

Co-author, “UPREITs and DownREITs: A Primer,” Major Tax Planning (USC Gould School of Law 68th Tax Institute), Matthew Bender 2016.

EXPERIENCE

Brian’s representative experience includes advising:

  • Iteris, a provider of intelligent transportation systems technology solutions, in its take-private acquisition by Almaviva
  • Teladoc, Inc. in its US$440 million acquisition of Best Doctors
  • Digital Realty Trust Inc. in its US$7.6 billion acquisition of DuPont Fabros Technology Inc.
  • Integra LifeSciences Holdings Corp. in its US$204 million acquisition of Derma Sciences Inc.
  • Ligand Pharmaceuticals, Inc. in its US$25 million acquisition of Crystal Bioscience Inc.
  • Transom Capital Group in its US$26 million acquisition of A.T. Cross Company
  • Underwriters in the US$75 million initial public offering of Obalon Therapeutics Inc.